Przejście menopawzalne i epilepsja: Fokus na leczenie

PubMed➕ 14.08.2026Neurol Clin Pract

The Menopause Transition and Epilepsy: A Focus on Therapeutics

W skrócie

Badanie dotyczy wpływu menopauzy na kobiety z epilepsją. W okresie menopauzy dochodzi do zmian hormonalnych, które mogą wpływać na częstość napadów i działanie leków przeciwpadaczkowych. Autorzy wskazują, że terapia hormonalna jest skuteczna w łagodzeniu objawów menopauzy, ale brakuje danych na temat jej bezpieczeństwa u kobiet z epilepsją, dlatego potrzebne są dalsze badania.

Oryginalny abstract (angielski)

PURPOSE OF THE REVIEW: Perimenopause and menopause are reproductive stages marked by fluctuating and subsequent permanent loss of ovarian estrogen and progesterone production. There are important considerations in these life stages for people with epilepsy including the influence of hormonal changes and use of menopausal hormone therapy (HT) on seizure control and on antiseizure medication (ASM) metabolism. This narrative review summarizes the currently available information about this topic to increase provider awareness and identify gaps in knowledge for future research. RECENT FINDINGS: Menopause is associated with symptoms that can negatively affect quality of life, including vasomotor and genitourinary symptoms, mood and sleep disturbances, and cognitive changes. HT is the most effective treatment for menopause symptoms, but data on HT use in women with epilepsy are limited. HT may influence seizure control and the metabolism of some ASMs, such as lamotrigine. These observations and the limited available data may be a deterrent to the use of HT in women with epilepsy. SUMMARY: Data are largely lacking to guide the management of epilepsy during perimenopause and menopause. This review summarizes existing data and discusses HT and nonhormone therapies for management of menopause symptoms, highlighting unique considerations for those with epilepsy during the menopause transition.

Metadane publikacji

Journal
Neurol Clin Pract
Data publikacji
01.10.2026
PMID
42594325
DOI
10.1212/CPJ.0000000000200650
Autorzy
Smith KM, Faubion SS, Vadlamudi L, Christakis M, Mostacci B, Cerulli Irelli E, Ortiz-Guerrero G, Cavitt J, Voinescu PE, Bui E
Źródło
PubMed